Phase I dose escalation safety study of nanoparticulate paclitaxel (CTI 52010) in normal dogs

BACKGROUND: Paclitaxel is highly effective in the treatment of many cancers in humans, but cannot be routinely used in dogs as currently formulated due to the exquisite sensitivity of this species to surfactant-solubilizing agents. CTI 52010 is a formulation of nanoparticulate paclitaxel consisting...

Descripción completa

Detalles Bibliográficos
Autores principales: Axiak, Sandra M, Selting, Kim A, Decedue, Charles J, Henry, Carolyn J, Tate, Deborah, Howell, Jahna, Bilof, K James, Kim, Dae Y
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2011
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3205122/
https://www.ncbi.nlm.nih.gov/pubmed/22072863
http://dx.doi.org/10.2147/IJN.S24823

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3205122/
https://www.ncbi.nlm.nih.gov/pubmed/22072863
http://dx.doi.org/10.2147/IJN.S24823

Ejemplares similares